Narrow search
Showing 1 - 10 of 15
Cover Image
Innovationsindikator 2012
Frietsch, Rainer; Rammer, Christian; Schubert, Torben; … - 2012
Der Innovationsindikator 2012 der Deutsche Telekom Stiftung und des Bundesverbands der Deutschen Industrie bewertet den aktuellen Stand der Innovationsleistung Deutschlands im Vergleich mit den wichtigsten Wettbewerbern auf den internationalen Märkten. Er fasst alle wesentlichen Faktoren in den...
Persistent link: https://www.econbiz.de/10010527582
Cover Image
Innovationsindikator 2015: Schwerpunkt mittelständische Wirtschaft
Frietsch, Rainer; Rammer, Christian; Schubert, Torben; … - 2015
Persistent link: https://www.econbiz.de/10011451722
Cover Image
The Current InsurTech Landscape: Business Models and Disruptive Potential
Braun, Alexander; Schreiber, Florian - 2017
We take a detailed look at the current InsurTech landscape from the angle of the academic management literature. Our main goals are to establish a common understanding of key concepts, to facilitate the navigation of this rapidly evolving sector, and to provide an intuitive toolkit for an...
Persistent link: https://www.econbiz.de/10012318598
Cover Image
Innovation and the global expansion of intellectual property rights: Unfulfilled promises
Correa, Carlos María - 2016
innovation will be boosted - do not match the reality. The effects of high standards of protection - as those mandated under the …]ntellectual property is …a social contrivance purportedly designed to increase welfare, by supposedly enhancing innovation (though… it may … little to promote local innovation and economic development. The scenario for innovation in the pharmaceutical sector clearly …
Persistent link: https://www.econbiz.de/10012490844
Cover Image
Eighteen years after Doha: An analysis of the use of public health TRIPS flexibilities in Africa
Vawda, Yousuf A.; Shozi, Bonginkosi - 2020
As we observe the 18th anniversary of the Doha Declaration on the TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights) and Public Health, it is appropriate to take stock of intellectual property developments and endeavour to present a comprehensive account of the...
Persistent link: https://www.econbiz.de/10012490879
Cover Image
Guide for the granting of compulsory licenses and government use of pharmaceutical patents
Correa, Carlos María - 2020
Like other rights, patent rights are not absolute. There are situations in which their exercise can be limited to protect public interests. Such situations may arise, for instance, when access to needed pharmaceutical products must be ensured. Compulsory licenses and government use for...
Persistent link: https://www.econbiz.de/10012490883
Cover Image
Guía para la concesión de licencias obligatorias y uso gubernamental de patentes farmacéuticas
Correa, Carlos María - 2020
Al igual que otros derechos, los derechos de patente no son absolutos. Hay situaciones en las que su ejercicio puede limitarse para proteger los intereses públicos. Esas situaciones pueden surgir, por ejemplo, cuando debe garantizarse el acceso a los productos farmacéuticos necesarios. Las...
Persistent link: https://www.econbiz.de/10012490884
Cover Image
Special Section 301: US interference with the design and implementation of national patent laws
Correa, Carlos M. - 2020
The continuous application of Special Section 301 by the Office of the United States Trade Representative (USTR) undermines the rule of law as a fundamental principle of a multilateral system based on the sovereign equality of states and the respect for international law. Interference with...
Persistent link: https://www.econbiz.de/10012490894
Cover Image
TRIPS flexibilities on patent enforcement: Lessons from some developed countries relating to pharmaceutical patent protection
Sarnoff, Joshua D. - 2020
access to medicines relative to providing innovation incentives. …
Persistent link: https://www.econbiz.de/10012490899
Cover Image
Designing pro-health competition policies in developing countries
Ido, Vitor Henrique Pinto - 2020
Competition law and policy has become an important tool for countries to promote access to pharmaceuticals. How can countries design and enforce competition policies that are suitable to the particularities of developing countries? What are the main anti-competitive tactics in the pharmaceutical...
Persistent link: https://www.econbiz.de/10012490907